Adam R. Hall received his training in physics and materials sciences at the University of North Carolina at Chapel Hill, where he was a NASA Graduate Student Research Program (GSRP) Fellow and received the Ross & Charlotte Johnson Family Dissertation Fellowship. He then spent three years as a postdoctoral researcher at Technische Universitat Delft in the Netherlands. From 2010-13, he was an Assistant Professor of Nanoscience at the Joint School of Nanoscience and Nanoengineering in Greensboro, NC, where he earned awards for both his research activities and teaching. He joined the faculty of the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences in August of 2013 as an Assistant Professor in the Wake Forest School of Medicine. He was promoted to Associate Professor with tenure in 2021 and was appointed Assistant Director of Translational Research for the Atrium Wake Forest Comprehensive Cancer Center in 2023. Dr. Hall has published more than 50 journal articles, is an inventor on 5 patents, and his research has been supported by diverse agencies including the National Institutes of Health (NCI, NIGMS, NIBIB, and NHGRI), DoD, BARDA, 3M, and the North Carolina Biotechnology Center. His research focuses on translational applications of micro- and nanotechnologies.

Andrew K. Godwin, PhD, the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor, is a leader in the field of translational research and precision medicine. A native of Lawrence, Kansas, Andy graduated with highest distinction from the University of Kansas with a bachelor’s degree in Cellular Biology. He obtained his PhD in Molecular Biology from the University of Pennsylvania while carrying out his thesis research at Fox Chase Cancer Center in Philadelphia. Andy holds the distinction of being the only graduate student at FCCC to become a senior member (full professor with tenure). While at FCCC he had the pleasure of learning from “giants” in their respective fields of science. He was appointed leader of the FCCC’s Cancer Center Support Grant Ovarian Cancer Program in 2008 and served as co-leader of the Women's Cancer Program from 2009 to 2010. He was also the director of both the Clinical Molecular Genetics/Pathology Laboratory and the Biosample Repository at FCCC since their inception in 1995 and 1999 respectively, until leaving FCCC.

Andy was recruited to KUMC as the Associate Director for Translational Research for the KU Cancer Center in October 2010 after 26 productive years at FCCC and his engaged participation contributions towards NCI designation in 2012/2017 and comprehensive designation in 2022, resulted in him being named the Deputy Director in 2013. He serves the director of Molecular Oncology at the KU Medical Center. In the latter position, he founded the Clinical Molecular Oncology Laboratory, a CLIA-certified, CAP-accredited molecular diagnostics laboratory, and heads KU’s institutional efforts in precision medicine. He was appointed the Division Director for Genomic Diagnostic for the KU Health System in 2020. He also founded the Center for Genetics Services and Health Equity, to address health disparities in our region and nationally. Andy holds secondary appointments as a Professor in the Department of Internal Medicine, and the Department of Microbiology, Molecular Genetics, and Immunology. He also leads the ovarian cancer research-working group, is a member of the Investigator Initiated Trial Steering Committee, serves as the Scientific Director for the Biomarker Discovery Laboratory, the Director of the KU Cancer Center’s Biospecimen Shared Resource, and the KU Medical Center’s Biospecimen Repository Core Facility. He was named the Vice Chair for the Breast Translational Medicine subcommittee of the Southwest Oncology Group in 2018 and was appointed to the National Cancer Institute’s NCTN Core Correlative Sciences Committee (NCTN-CCSC) in 2021.

Andy is the founding director of the Kansas Institute for Precision Medicine Centers of Biomedical Research Excellence (COBRE) (P20 GM130423). He was named a Kansas Bioscience Authority Eminent Scholar in 2010 and the University of Kansas School of Medicine Chancellor’s Distinguished Chair in Biomedical Sciences Endowed Professor in 2012. In 2014, Andy received the KUMC School of Medicine’s Achievement Award for the mentoring of post-doctorate students. Of his awards, he is most proud of being acknowledged for his years of mentoring. He has mentored over 150 trainees, including high school students, undergraduates, graduate students, postdoctoral associates/fellows, medical students/fellows, visiting scientists, and junior faculty during his academic career.

Prof. Cunningham has been a faculty member in the department of Electrical and Computer Engineering and the department Bioengineering at the University of Illinois at Urbana-Champaign since 2004, following a 15-year career in Industry. Prof. Cunningham’s technical focus is the utilization of photonics for biosensing in applications that include life science research, diagnostics, environmental monitoring, and pharmaceutical screening. He has over 90 issued US patents and over 200 peer reviewed journal publications. He is a Fellow of NAI, IEEE, Optica, RSC, AAAS, and AIMBE. He serves as the Director of the Center for Genomic Diagnostics at the Woese Institute for Genomic Biology, and as a Program Leader for the Cancer Center at Illinois on the topic of Cancer Measurement Technology and Data Science. In 2023, his technical contributions were recognized by Optica by the Michael S. Feld Biophotonics Award.

Daniel T. Chiu is currently the A. Bruce Montgomery Professor Chemistry, Endowed Professor of Analytical Chemistry, and Professor of Bioengineering at the University of Washington. He is a member of the University of Washington’s Center for Nanotechnology, Neurobiology and Behavior Program, and the Cancer Consortium of the Fred Hutchinson Cancer Research Center. He has authored more than 180 publications and is the inventor on over 40 issued patents. Dr. Chiu obtained a B.A. in neurobiology and a B.S. in chemistry at the University of California, Berkeley in 1993, and a Ph.D. in chemistry from Stanford University in 1998.

David T.W. Wong DMD, DMSc is Felix & Mildred Yip Endowed Professor, Associate Dean of Research and Director of the Oral/Head and Neck Oncology Research Center at UCLA. Dr. Wong is an active scientist in oral cancer and saliva diagnostics research. He has authored over 280 peer reviewed scientific publications. He is a fellow of the American Association for the Advancement of Sciences (AAAS), past member of the ADA Council of Scientific Affairs and the past president of American Association of Dental Research (AADR).

Erik specializes in EU and national legal and regulatory issues relating to medical devices, including eHealth, mHealth, software and protection of personal data. He is an expert in life sciences regulation at EU and Dutch level, with a focus on contracts, regulatory litigation against competent authorities and M&A. Erik was initially trained as intellectual property and competition lawyer, starting his career at the Directorate-General for Competition of the European Commission. He subsequently gained experience in contentious matters, commercial contracts, and transactional work at three large international law firms. He actively contributes to law and policy development at national and EU level via membership of specialized committees at branch associations and the European Commission. Erik also works as arbitrator in medical devices related disputes and is regularly retained as expert witness in foreign litigation.

Dr. Hyungsoon Im is Associate Professor of Radiology at Harvard Medical School and Massachusetts General Hospital. His research aims to bridge engineering and medicine fields by developing next-generation diagnostic sensing technologies to better understand the makeup of human diseases and changes associated with disease progression and therapy. He also develops and applies artificial intelligence (AI) to multiomics data to improve data analysis accuracies and robustness. Dr. Im has been actively working with clinical investigators both in and outside of MGH to validate my technologies for clinical samples and apply them in clinical settings.

Jaebum Choo is a Professor in the Department of Chemistry at Chung-Ang University in South Korea. He earned his Ph.D. from Texas A&M University in 1994. From 1995 to 2019, he served as a faculty member at Hanyang University. In 2015, he was appointed as a Baik Nam Distinguished Professor, acknowledging his outstanding academic accomplishments. In 2016, he served as the President of the Korea Biochip Society, and in 2020, he chaired the Analytical Chemistry Division of the Korean Chemical Society. Currently, Professor Choo holds the position of Vice-President for Research at Chung-Ang University and serves as the Director of the "Center for Nanophotonics-based Biomedical Diagnostics Research Center (ERC)," supported by the National Research Foundation of Korea. He is currently the associate editor of Analyst at the Royal Society of Chemistry and a member of the editorial board for ACS Sensors and Analytical Chemistry at the American Chemical Society. His ongoing research programs focus on developing highly sensitive optical nano-sensor systems for rapid and precise in vitro diagnostics of infectious diseases. Throughout his career, Professor Choo has delivered over 150 invited lectures in the USA, Europe, and Asia. He has published more than 300 research papers in peer-reviewed journals (with ~22,000 citations and an H-index of 76) and has contributed to eight book chapters.

Martyn Boutelle is Professor of Biomedical Sensors Engineering in the Department of Bioengineering, Imperial College London, and Associate Provost for Estates Planning for Imperial College.
His research group is multidisciplinary comprising, bioengineers, scientists, and clinicians. He develops novel analytical science methods using microfluidics, electrochemical sensors / biosensors, and wireless electronics to make portable (sometimes wearable) monitoring devices for use as point of care devices that typically giving continuous real -time displays. He then uses these in a program of clinical science research focusing on the acute traumatic brain injury including that caused by cardiac arrest, neonatal continuous monitoring and kidney transplantation monitoring. He runs the EPSRC funded Bio-nanofabrication suite designed to make microfluidic and biosensor biosensors using scalable methods to allow use in proof-of-concept clinical trials.

Martyn is past president of the International Society for Monitoring Molecules in Neuroscience, and a founder of the COSBID organization for studying acute human brain injury. He published > 190 papers, chapters and patents. He obtained a BSc and PhD in Chemistry from Imperial College and worked as an EP Abraham Research Fellow in the University of Oxford.

Paul W. Bohn received the B.S. from the University of Notre Dame in 1977 and the Ph.D. from the University of Wisconsin-Madison in 1981, both in Chemistry. After two years at Bell Laboratories, he joined the faculty at the University of Illinois at Urbana-Champaign (UIUC). In 2006, he moved to the University of Notre Dame where he is currently the Arthur J. Schmitt Professor of Chemical and Biomolecular Engineering, Professor of Chemistry and Biochemistry, and Director of the Institute for Precision Health. He served as Editor for the Americas for the RSC journal Analyst 2007-09 and as Chair of the Editorial Board 2010-14. Prof. Bohn is currently co-editor of Annual Review of Analytical Chemistry. His research interests include: (a) integrated nanofluidic and microfluidic chemical measurement strategies for personal monitoring, (b) chemical and biochemical sensing in mass-limited samples, (c) biochemical imaging, and (d) molecular approaches to nanotechnology, areas in which he has over 290 publications and 10 patents.

Prof. Whelan is Associate Professor of Chemistry at the University of Kansas. She is also affiliated with the Adams Institute for Bioanalytical Chemistry and the KU Cancer Center. She earned her Ph.D. at Stanford University and did postdoctoral research at the University of Michigan. Research during her independent career has focused on applications of separations, affinity agent development, and proteomics to ovarian cancer biomarker characterization and detection.

Prof. Soper (since 2016) is a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas. At KUMC, Prof. Soper holds an adjunct appointment in the Cancer Biology Department and is a member of the KU Cancer Center. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.

As a result of his efforts, Prof. Soper has secured extramural funding totaling >$125M, has published over 245 peer-reviewed manuscripts (h index = 70; >17,000 citations); 31 book chapters and 71 peer-reviewed conference proceeding papers, and is the author of 12 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of liquid biopsy markers. Soper recently founded a second company, Sunflower Genomics, which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Ralph Adams Award in Bioanalytical Chemistry, Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 50 PhDs and 7 MS degrees to students under his mentorship. He currently heads a group of 15 researchers.

His major discoveries include: (1) Technology for the detection of liquid biopsy markers that can manage a variety of diseases using a simple blood test (test has been demonstrated in multiple myeloma, pediatric acute lymphoblastic leukemia, acute myeloid leukemia, pancreatic, breast, colorectal, prostate, and ovarian cancers); (2) new hardware and assay for the point-of-care diagnosis of acute ischemic stroke; (3) single-molecule DNA and RNA sequencing nanotechnology; and (4) currently working on a home-test for COVID-19 infections (handheld instrument and the associated assay.

Dr. Tony Hu is a Professor in Biochemistry and Molecular Biology, Biomedical Engineering, and Microbiology at Tulane University. He is also the Weatherhead Presidential Chair in Biotechnology Innovation, founding Director of the Center for Intelligent Molecular Diagnostics at Tulane School of Medicine, and the fellows of National Academy of Inventors (NAI) and American Institute of Medical and Biological Engineering (AIMBE). Dr. Hu’s research focuses on engineered multi-omics, nanomedicine, mechanism-driven biomarker discovery and assay development. His research differs from conventional biomarker discovery and detection research for clinical microbiology in that it employs the special properties of nanomaterials to improve assay performance and reproducibility. His inventions are intended to serve as a model for the analysis of similar characteristics of infectious and malignant diseases to facilitate the development of a full spectrum of diagnostic, prognostic and treatment evaluation assays, and re-define the diagnostic criteria to differentiate disease stages using molecular tests as a long-term goal. His work has resulted in publications of over 150 high-impact papers, and 25 pat¬ent applications involving nanomedicine. Fourteen of those patents have been licensed by US-based or international companies. Dr. Hu’s lab has been consistently support¬ed by the DOD, NIH, Gates Foundation, WHO and others. Dr. Hu is also the co-founders of two biotech startup companies, Intelligenome Inc. in Houston, TX and NanoPin Technologies in New Orleans, LA.

Yoon-Kyoung Cho is a full professor of Biomedical Engineering at UNIST and a group leader in the Center for Soft and Living Matter at the Institute for Basic Science (IBS), Republic of Korea. She is a member of the National Academy of Engineering of Korea (NAEK) and a Fellow of Royal Society of Chemistry (FRSC). She serves as a director at the Chemical and Biological Microsystems Society (CBMS) and an associate editor for Lab on a chip. She received her Ph.D. in Materials Science and Engineering from the University of Illinois at Urbana-Champaign (UIUC) in 1999, having obtained her M.S. and B.S. in Chemical Engineering from POSTECH in 1994 and 1992, respectively. She worked as a senior researcher (1999–2008) at Samsung Advanced Institute of Technology (SAIT), where she helped create biomedical in vitro diagnostic instruments. Her research spans a broad spectrum from fundamental scientific exploration to translational efforts, focusing primarily on microfluidics and nanomedicine. Her current research topics include a lab-on-a-disc for the detection of rare cells and biomarkers, quantitative analysis of single cells, and system analysis of cellular communication. She published over 135 journal papers and over 205 issued patents, many of which helped Samsung Electronics and two start-ups (Clinomics and LabSpinner) build commercial products. Discover more at http://fruits.unist.ac.kr.